Clinical Trial Detail

NCT ID NCT03711058
Title Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Indications

colon cancer

Advanced Solid Tumor

Therapies

Copanlisib + Nivolumab

Age Groups: senior

Additional content available in CKB BOOST